CU24049B1 - POLYMORPH B OF THE N- (2-AMINOPHENYL) -4- [N- (PIRIDIN-3-IL) METOXICARBONYLAMINE-METHYL] BENZAMIDE (MS-275) - Google Patents

POLYMORPH B OF THE N- (2-AMINOPHENYL) -4- [N- (PIRIDIN-3-IL) METOXICARBONYLAMINE-METHYL] BENZAMIDE (MS-275)

Info

Publication number
CU24049B1
CU24049B1 CU2011000044A CU20110044A CU24049B1 CU 24049 B1 CU24049 B1 CU 24049B1 CU 2011000044 A CU2011000044 A CU 2011000044A CU 20110044 A CU20110044 A CU 20110044A CU 24049 B1 CU24049 B1 CU 24049B1
Authority
CU
Cuba
Prior art keywords
aminophenyl
benzamide
methyl
polymorph
metoxicarbonylamine
Prior art date
Application number
CU2011000044A
Other languages
Spanish (es)
Other versions
CU20110044A7 (en
Inventor
Matthias Schneider
Michael Gottfried
Jens Geisler
Gabriele Winter
Original Assignee
Bayer Ip Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/EP2009/006381 external-priority patent/WO2010022988A1/en
Application filed by Bayer Ip Gmbh filed Critical Bayer Ip Gmbh
Publication of CU20110044A7 publication Critical patent/CU20110044A7/en
Publication of CU24049B1 publication Critical patent/CU24049B1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4406—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 3, e.g. zimeldine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/63—One oxygen atom
    • C07D213/65—One oxygen atom attached in position 3 or 5
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)

Abstract

El polimorfo B cristalino de N-(2-aminofenil)-4-[N-(piridin-3-il)metoxicarbonilamino-metil]benzamida (MS-275) de fórmula I ESPACIO PARA LA FÓRMULA el cual es útil para tratar tumores malignos, enfermedades autoinmunes, enfermedades dermatológicas y parasitismo. También se describe el proceso para producir dicho compuesto.The crystalline polymorph B of N- (2-aminophenyl) -4- [N- (pyridin-3-yl) methoxycarbonylamino-methyl] benzamide (MS-275) of formula I SPACE FOR FORMULA which is useful for treating malignant tumors , autoimmune diseases, dermatological diseases and parasitism. The process for producing said compound is also described.

CU2011000044A 2008-08-29 2011-02-28 POLYMORPH B OF THE N- (2-AMINOPHENYL) -4- [N- (PIRIDIN-3-IL) METOXICARBONYLAMINE-METHYL] BENZAMIDE (MS-275) CU24049B1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US9304608P 2008-08-29 2008-08-29
PCT/EP2009/006381 WO2010022988A1 (en) 2008-08-29 2009-08-27 N-(2-aminophenyl)-4-[n-(pyridine-3-yl)-methoxycarbonyl-aminomethyl]-benzamide (ms-275)polymorph b

Publications (2)

Publication Number Publication Date
CU20110044A7 CU20110044A7 (en) 2011-12-28
CU24049B1 true CU24049B1 (en) 2014-12-26

Family

ID=40791975

Family Applications (1)

Application Number Title Priority Date Filing Date
CU2011000044A CU24049B1 (en) 2008-08-29 2011-02-28 POLYMORPH B OF THE N- (2-AMINOPHENYL) -4- [N- (PIRIDIN-3-IL) METOXICARBONYLAMINE-METHYL] BENZAMIDE (MS-275)

Country Status (2)

Country Link
CU (1) CU24049B1 (en)
GB (1) GB2462893B (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2977492B1 (en) * 2011-07-04 2013-07-05 Servier Lab NOVEL ASSOCIATION BETWEEN N-HYDROXY-4- {2- [3- (N, N-DIMETHYLAMINOMETHYL) BENZOFURAN-2-YLCARBONYLAMINO] ETHOXY} BENZAMIDE AND FOLFOX

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6174905B1 (en) * 1996-09-30 2001-01-16 Mitsui Chemicals, Inc. Cell differentiation inducer
US6794392B1 (en) * 1996-09-30 2004-09-21 Schering Aktiengesellschaft Cell differentiation inducer
JP2001064177A (en) * 1999-08-16 2001-03-13 Schering Ag Pharmaceutical preparation including benzamide derivative as ingredient
JP4360660B2 (en) * 1999-11-09 2009-11-11 三井化学株式会社 Purification method of monoacylphenylenediamine derivatives
PE20050206A1 (en) * 2003-05-26 2005-03-26 Schering Ag PHARMACEUTICAL COMPOSITION CONTAINING AN INHIBITOR OF HISTONE DEACETILASE

Also Published As

Publication number Publication date
CU20110044A7 (en) 2011-12-28
GB0907347D0 (en) 2009-06-10
GB2462893B (en) 2010-10-13
GB2462893A (en) 2010-03-03

Similar Documents

Publication Publication Date Title
PH12015501585A1 (en) Manufacturing process for pyrimidine derivatives
GEP20146131B (en) Carbazole compounds and therapeutic uses thereof
CR20160465A (en) POLYMORPH B OF THE N- (2-AMINOPHENYL) -4- [N- (PIRIDIN-3-IL) METOXICARBONYLAMINE-METHYL] BENZAMIDE (MS-275)
EA201000113A1 (en) PYRAZOL COMPOUNDS
EA201690153A1 (en) SUBSTITUTED PETROPHORANE AND BENZOXAZOLYL COMPOUNDS AND THEIR APPLICATIONS
EA201101650A1 (en) NEW PYRIMIDINE DERIVATIVES AND THEIR APPLICATION IN THE TREATMENT OF MALIGNANT NONFORMS AND THE FOLLOWING DISEASES
EA201001848A1 (en) DERIVATIVES OF PIRAZINE AS EPITELIAL SODIUM CHANNEL BLOCKS
EA201100299A1 (en) ORGANIC COMPOUNDS
CU24269B1 (en) 3- PIRIMIDIN- 4-IL- OXAZOLIDIN- 2- INHIBITING WAVES OF THE MUTANT HDI
EA201270752A1 (en) KINASE INHIBITORS AND METHOD FOR TREATING MALIGNANT TUMOR WITH THEIR HELP
ECSP109987A (en) METHODS AND USEFUL COMPOUNDS TO PREPARE INHIBITORS OF THE 2-GLUCOSE CO-TRANSPORTER SODIUM
EA201100503A1 (en) GLUCOSIDE DERIVATIVES AND THEIR APPLICATIONS
EA201400245A1 (en) INHIBITORS DYRK1 AND THEIR APPLICATION
EA201170154A1 (en) DERIVATIVES OF PYRIDINOPIRIDINONES, METHOD OF THEIR RECEPTION AND APPLICATION IN THERAPY
EA201170617A1 (en) PYRAZOLYLAMINOPIRIDINE AS FAK INHIBITORS
BR112022009390A2 (en) IMPROVED SYNTHESIS OF KRAS INHIBITOR COMPOUND G12C
EA201291246A1 (en) CONDENSED BICYCLIC KINASE INHIBITORS
NO20080445L (en) New azetidine derivatives as neurokinin receptor antagonists for the treatment of gastrointestinal disorders
TW200635905A (en) Processes for producing 4-aminoquinazolines
GT200600207A (en) PROCESS FOR THE SYNTHESIS OF ORGANIC COMPOUNDS
EA201170672A1 (en) COMPOUNDS SUITABLE FOR THE TREATMENT OF CELLULITE
EA201690755A1 (en) SALT AND CRYSTAL FORMS OF PLK-4 INHIBITOR
TNSN06260A1 (en) Process for the preparation of tryptase inhibitors
EA201001566A1 (en) NEW CLASS OF SPYROPIPERIDINES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES
SG10201902903RA (en) Synthesis and novel salt forms of (r)-5-((e)-2-(pyrrolidin-3-ylvinyl)pyrimidine

Legal Events

Date Code Title Description
FG Grant of patent